688488 艾迪药业
午间休市 10-13 11:29:55
资讯
新帖
简况
艾迪药业（688488）10月12日主力资金净卖出417.68万元
证券之星 · 08:33
艾迪药业（688488）10月12日主力资金净卖出417.68万元
10月8日艾迪药业跌7.52%，华商科创创业精选混合A基金重仓该股
证券之星 · 10-08
10月8日艾迪药业跌7.52%，华商科创创业精选混合A基金重仓该股
艾迪药业（688488）9月29日主力资金净买入1399.77万元
证券之星 · 09-30
艾迪药业（688488）9月29日主力资金净买入1399.77万元
9月21日艾迪药业涨8.21%，华商科创创业精选混合A基金重仓该股
证券之星 · 09-21
9月21日艾迪药业涨8.21%，华商科创创业精选混合A基金重仓该股
连亏5年股艾迪药业调降定增募资金额 为兴全基金重仓股
中金财经 · 09-18
连亏5年股艾迪药业调降定增募资金额 为兴全基金重仓股
艾迪药业最新公告：拟定增募资不超9.45亿元用于新型HIV整合酶抑制剂全球临床开发项目等
证券之星 · 09-17
艾迪药业最新公告：拟定增募资不超9.45亿元用于新型HIV整合酶抑制剂全球临床开发项目等
江苏艾迪药业调整定增方案：拟募资上限降至9.45亿元，较此前公布的13亿元有所缩减
美股速递 · 09-17
江苏艾迪药业调整定增方案：拟募资上限降至9.45亿元，较此前公布的13亿元有所缩减
每周股票复盘：艾迪药业（688488）将参加科创板业绩说明会
证券之星 · 09-13
每周股票复盘：艾迪药业（688488）将参加科创板业绩说明会
艾迪药业（688488）披露2025年股票期权激励计划部分股票期权注销完成公告，9月8日股价下跌0.84%
证券之星 · 09-08
艾迪药业（688488）披露2025年股票期权激励计划部分股票期权注销完成公告，9月8日股价下跌0.84%
艾迪药业：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
证券日报网 · 09-07
艾迪药业：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告
艾迪药业（688488）披露2026年半年度报告，8月31日股价上涨0.74%
证券之星 · 08-31
艾迪药业（688488）披露2026年半年度报告，8月31日股价上涨0.74%
艾迪药业（688488）2026年中报简析：营收净利润同比双双增长
证券之星 · 08-30
艾迪药业（688488）2026年中报简析：营收净利润同比双双增长
图解艾迪药业中报：第二季度单季净利润同比增长339.83%
证券之星 · 08-29
图解艾迪药业中报：第二季度单季净利润同比增长339.83%
每周股票复盘：艾迪药业（688488）实控人一致行动人质押1.07%股份
证券之星 · 08-23
每周股票复盘：艾迪药业（688488）实控人一致行动人质押1.07%股份
艾迪药业（688488）披露实际控制人之一致行动人部分股份质押公告，8月18日股价下跌2.32%
证券之星 · 08-18
艾迪药业（688488）披露实际控制人之一致行动人部分股份质押公告，8月18日股价下跌2.32%
艾迪药业（688488）股东傅和祥质押450万股，占总股本1.07%
证券之星 · 08-18
艾迪药业（688488）股东傅和祥质押450万股，占总股本1.07%
每周股票复盘：艾迪药业（688488）完成收购南大药业少数股权
证券之星 · 08-16
每周股票复盘：艾迪药业（688488）完成收购南大药业少数股权
股市必读：艾迪药业新发布《艾迪药业关于公司收购控股子公司少数股东股权进展的公告》
证券之星 · 08-14
股市必读：艾迪药业新发布《艾迪药业关于公司收购控股子公司少数股东股权进展的公告》
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，8月12日股价下跌1.16%
证券之星 · 08-12
艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，8月12日股价下跌1.16%
每周股票复盘：艾迪药业（688488）董事傅和亮增持7.06万股
证券之星 · 08-09
每周股票复盘：艾迪药业（688488）董事傅和亮增持7.06万股
加载更多
公司概况
公司名称：
江苏艾迪药业集团股份有限公司
所属行业：
其他制造业
上市日期：
2020-07-20
主营业务：
江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是艾诺韦林片、艾诺米替片、注射用尿激酶。公司是国家级高新技术企业。
发行价格：
13.99
{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":14.3,"timestamp":1791862195000,"preClose":15,"halted":0,"volume":4757505,"delay":0,"changeRate":-0.0467,"floatShares":421000000,"shares":421000000,"eps":-0.0138,"marketStatus":"午间休市","change":-0.7,"latestTime":"10-13 11:29:55","open":14.69,"high":14.89,"low":14.03,"amount":68129200,"amplitude":0.0573,"askPrice":14.37,"askSize":12,"bidPrice":14.32,"bidSize":10,"shortable":0,"etf":0,"ttmEps":-0.0138,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791867600000},"marketStatusCode":3,"adr":0,"adjPreClose":15,"symbolType":"stock_kcb","openAndCloseTimeList":[[1791855000000,1791862200000],[1791867600000,1791874800000]],"highLimit":16.5,"lowLimit":13.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"isCdr":false,"pbRate":6.9,"roa":"--","roe":"2.41%","epsLYR":-0.05,"committee":-0.188976,"marketValue":6017000000,"turnoverRate":0.0113,"status":1,"floatMarketCap":6017000000},"requestUrl":"/m/hq/s/688488","defaultTab":"news","newsList":[{"id":"2675386125","title":"艾迪药业（688488）10月12日主力资金净卖出417.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675386125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675386125?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:33","pubTimestamp":1791851637,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月12日收盘，艾迪药业报收于15.0元，下跌4.76%，换手率1.37%，成交量5.76万手，成交额8779.66万元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入748.12万元，融资偿还586.98万元，融资净买入161.14万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300007214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027599","title":"10月8日艾迪药业跌7.52%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673027599?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:40","pubTimestamp":1791448854,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日艾迪药业跌7.52%，收盘报15.38元，换手率2.28%，成交量9.6万手，成交额1.51亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A目前规模为1.96亿元，最新净值1.8269，较上一交易日下跌2.18%。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488","159781"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671918225","title":"艾迪药业（688488）9月29日主力资金净买入1399.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671918225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671918225?lang=zh_cn&edition=full","pubTime":"2026-09-30 08:23","pubTimestamp":1790727806,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月29日收盘，艾迪药业报收于16.12元，上涨2.74%，换手率1.83%，成交量7.71万手，成交额1.25亿元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入1049.12万元，融资偿还893.57万元，融资净买入155.55万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000006581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669596041","title":"9月21日艾迪药业涨8.21%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669596041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669596041?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980165,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日艾迪药业涨8.21%，收盘报16.6元，换手率3.37%，成交量14.18万手，成交额2.31亿元。重仓艾迪药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","159781","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668943675","title":"连亏5年股艾迪药业调降定增募资金额 为兴全基金重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668943675","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668943675?lang=zh_cn&edition=full","pubTime":"2026-09-18 14:52","pubTimestamp":1789714326,"startTime":"0","endTime":"0","summary":"中国经济网北京9月18日讯 艾迪药业 昨晚发布关于2026年度向特定对象发行A股股票方案及预案修订情况说明的公告。 公司对本次向特定对象发行A股股票的募投项目及募集资金金额相关事项以及公司实际控制人傅和亮作为发行对象之一的认购方式进行了调整，调整后的募投项目及募集资金总额不超过94,498.32万元(含本数)，扣除发行费用后净额拟用于新型HIV整合酶抑制剂全球临床开发项目、年产5亿片抗艾滋病固体制剂药物项目、补充流动资金。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/18/20260918168954.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/18/20260918168954.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260918/32374315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668596917","title":"艾迪药业最新公告：拟定增募资不超9.45亿元用于新型HIV整合酶抑制剂全球临床开发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2668596917","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668596917?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:00","pubTimestamp":1789642834,"startTime":"0","endTime":"0","summary":"艾迪药业(688488.SH)公告称，公司董事会审议通过2026年度向特定对象发行A股股票方案，拟募资总额不超过9.45亿元，用于新型HIV整合酶抑制剂全球临床开发项目、年产5亿片抗艾滋病固体制剂药物项目及补充流动资金。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187101379","title":"江苏艾迪药业调整定增方案：拟募资上限降至9.45亿元，较此前公布的13亿元有所缩减","url":"https://stock-news.laohu8.com/highlight/detail?id=1187101379","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187101379?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:00","pubTimestamp":1789642811,"startTime":"0","endTime":"0","summary":"江苏艾迪药业宣布，计划通过非公开发行股票方式募集资金，募资总额上限调整为9.45亿元。这一数字较该公司早前披露的13亿元募资计划，出现了明显下调。从原先的13亿元目标收缩至9.45亿元，降幅约达27.3%，显示出企业根据市场环境及自身资金需求状况，对资本运作方案作出的重新规划与优化。未来，艾迪药业将如何利用这笔资金布局核心业务，以及新方案能否顺利获得监管批准并落地实施，无疑将成为投资者关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507902","title":"每周股票复盘：艾迪药业（688488）将参加科创板业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507902","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507902?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:14","pubTimestamp":1789236852,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，艾迪药业报收于14.13元，较上周的15.44元下跌8.48%。本周，艾迪药业9月8日盘中最高价报15.63元。本周关注点公司公告汇总：艾迪药业将参加科创板2026年半年度创新药行业集体业绩说明会。艾迪药业关于2025年股票期权激励计划部分股票期权注销完成的公告江苏艾迪药业集团股份有限公司因2025年股票期权激励计划部分激励对象个人情况发生变化及公司层面业绩考核目标未成就，决定注销已授予但未行权的股票期权合计4,960,000份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321508","title":"艾迪药业（688488）披露2025年股票期权激励计划部分股票期权注销完成公告，9月8日股价下跌0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665321508?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:59","pubTimestamp":1788861566,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，艾迪药业报收于15.41元，较前一交易日下跌0.84%，最新总市值为64.84亿元。艾迪药业当日发布《关于2025年股票期权激励计划部分股票期权注销完成的公告》。公告显示，公司因2025年股票期权激励计划部分激励对象个人情况发生变化及公司层面业绩考核目标未成就，决定注销已授予但未行权的股票期权合计4,960,000份。公司已于2026年8月28日召开第三届董事会第十八次会议审议通过相关议案，并于近日完成注销手续。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319730","title":"艾迪药业：关于参加科创板2026年半年度创新药行业集体业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319730","media":"证券日报网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665319730?lang=zh_cn&edition=full","pubTime":"2026-09-07 18:01","pubTimestamp":1788775260,"startTime":"0","endTime":"0","summary":"证券日报网讯9月7日，艾迪药业发布公告称，公司计划于2026年9月16日15：00-17：00参与由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-07/doc-iniqyzxw5472550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0262","MEDX","KSTR","LNGR","BK1574","688488","IBBQ","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663072598","title":"艾迪药业（688488）披露2026年半年度报告，8月31日股价上涨0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663072598","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663072598?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:37","pubTimestamp":1788172633,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，艾迪药业报收于16.24元，较前一交易日上涨0.74%，最新总市值为68.34亿元。该股当日开盘16.0元，最高16.51元，最低15.85元，成交额达1.41亿元，换手率为2.07%。公司于近日披露《2026年半年度报告》。本期营业收入为365,854,758.25元，同比增长0.93%；利润总额为37,031,904.19元，同比增长13.71%；归属于上市公司股东的净利润为22,934,073.66元，同比增长149.53%；归属于上市公司股东的扣除非经常性损益的净利润为20,456,682.62元，上年同期为-5,112,714.15元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663176048","title":"艾迪药业（688488）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2663176048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663176048?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:17","pubTimestamp":1788041833,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期艾迪药业发布2026年中报。根据财报显示，艾迪药业营收净利润同比双双增长。截至本报告期末，公司营业总收入3.66亿元，同比上升0.93%，归母净利润2293.41万元，同比上升149.53%。按单季度数据看，第二季度营业总收入1.88亿元，同比上升14.1%，第二季度归母净利润1532.78万元，同比上升339.83%。本文数据来源于艾迪药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663018426","title":"图解艾迪药业中报：第二季度单季净利润同比增长339.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663018426","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663018426?lang=zh_cn&edition=full","pubTime":"2026-08-29 02:37","pubTimestamp":1787942237,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业2026年中报显示，上半年度公司主营收入3.66亿元，同比上升0.93%；归母净利润2293.41万元，同比上升149.53%；扣非净利润2045.67万元，同比上升500.11%；其中2026年第二季度，公司单季度主营收入1.88亿元，同比上升14.1%；单季度归母净利润1532.78万元，同比上升339.83%；单季度扣非净利润1188.27万元，同比上升194.97%；负债率50.67%，投资收益-35.64万元，财务费用793.91万元，毛利率65.49%。财报数据概要请见下图:本文数据来源于艾迪药业2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661902211","title":"每周股票复盘：艾迪药业（688488）实控人一致行动人质押1.07%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2661902211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661902211?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:58","pubTimestamp":1787421491,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，艾迪药业报收于16.49元，较上周的18.15元下跌9.15%。本周，艾迪药业8月20日盘中最高价报18.88元。本周关注点公司公告汇总：实际控制人之一致行动人傅和祥质押所持股份的34.14%，占公司总股本的1.07%。质押用于自身资金需求，质权人为深圳市深担增信融资担保有限公司，质押起始日为2026年8月17日，到期日以质权人申请解除质押为准。本次质押前无累计质押，本次质押后累计质押4,500,000股。已质押及未质押股份中均无冻结或限制股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660049871","title":"艾迪药业（688488）披露实际控制人之一致行动人部分股份质押公告，8月18日股价下跌2.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660049871","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660049871?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:10","pubTimestamp":1787062234,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，艾迪药业报收于17.3元，较前一交易日下跌2.32%，最新总市值为72.8亿元。近日，艾迪药业发布关于实际控制人之一致行动人部分股份质押的公告。公告显示，公司实际控制人傅和亮先生的一致行动人傅和祥先生持有公司股份13,179,944股，占公司总股本的3.13%。本次质押股份4,500,000股，占其所持股份的34.14%，占公司总股本的1.07%。质权人为深圳市深担增信融资担保有限公司，质押起始日为2026年8月17日，到期日以质权人申请解除质押为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800042298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469920","title":"艾迪药业（688488）股东傅和祥质押450万股，占总股本1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469920","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660469920?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:26","pubTimestamp":1787048794,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业8月18日公开信息显示，股东傅和祥向深圳市深担增信融资担保有限公司合计质押450.0万股，占总股本1.07%。质押详情见下表：截止本公告日，股东傅和祥已累计质押股份450.0万股，占其持股总数的34.14%。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。本文数据来源于艾迪药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800035159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175970","title":"每周股票复盘：艾迪药业（688488）完成收购南大药业少数股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175970","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175970?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:40","pubTimestamp":1786815621,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，艾迪药业报收于18.15元，较上周的17.54元上涨3.48%。本周关注点来自公司公告汇总：艾迪药业完成收购南大药业22.2324%少数股权，持股比例升至73.3580%。公司公告汇总艾迪药业已完成收购控股子公司南京南大药业有限责任公司少数股东华泰国信、道兴创投及姚繁狄合计持有的22.2324%股权。本次交割完成后，艾迪药业持有南大药业73.3580%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659615851","title":"股市必读：艾迪药业新发布《艾迪药业关于公司收购控股子公司少数股东股权进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659615851","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659615851?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:55","pubTimestamp":1786643715,"startTime":"0","endTime":"0","summary":"公司公告汇总：艾迪药业已完成收购南大药业22.2324%少数股权，持股比例升至73.3580%，相关工商变更及董事会调整已落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658973566","title":"艾迪药业（688488）披露收购控股子公司少数股东股权进展公告，8月12日股价下跌1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658973566","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658973566?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:22","pubTimestamp":1786526566,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，艾迪药业报收于17.08元，较前一交易日下跌1.16%，最新总市值为71.87亿元。近日，艾迪药业发布《关于公司收购控股子公司少数股东股权进展的公告》。公告显示，江苏艾迪药业集团股份有限公司已完成收购控股子公司南京南大药业有限责任公司少数股东华泰国信、道兴创投及姚繁狄合计持有的22.2324%股权。本次交割完成后，艾迪药业持有南大药业73.3580%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200029234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658067526","title":"每周股票复盘：艾迪药业（688488）董事傅和亮增持7.06万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658067526","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658067526?lang=zh_cn&edition=full","pubTime":"2026-08-09 03:20","pubTimestamp":1786216820,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，艾迪药业报收于17.54元，较上周的13.83元上涨26.83%。本周，艾迪药业8月7日盘中最高价报17.74元。8月3日盘中最低价报12.99元。艾迪药业当前最新总市值73.81亿元，在生物制品板块市值排名35/51，在两市A股市值排名2336/5205。本周关注点股本股东变化：董事傅和亮于7月31日增持7.06万股，占总股本0.0168%。变动期间公司股价上涨2.22%，当日收盘价为13.83元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791865784790,"stockEarnings":[{"period":"1week","weight":-0.098},{"period":"1month","weight":0.0616},{"period":"3month","weight":-0.0458},{"period":"6month","weight":-0.2686},{"period":"1year","weight":0.0345},{"period":"ytd","weight":-0.0814}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏艾迪药业集团股份有限公司","boardCode":"AI0041","boardName":"其他制造业","stockholders":"12168人(较上一季度增加4.00%)","perCapita":"34581股","listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","registeredCapital":"42078万元","survey":" 江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是艾诺韦林片、艾诺米替片、注射用尿激酶。公司是国家级高新技术企业。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}